PULMPulmatrix, Inc.

Nasdaq pulmatrix.com


$ 2.00 $ -0.04 (-1.92 %)    

Friday, 19-Apr-2024 13:23:19 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 2.04
$ 1.95
$ 0.00 x 0
$ 0.00 x 0
$ 1.95 - $ 2.00
$ 1.55 - $ 3.14
6,762
na
7.45M
$ 0.75
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-28-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-12-2023 03-31-2023 10-Q
5 03-30-2023 12-31-2022 10-K
6 11-10-2022 09-30-2022 10-Q
7 08-10-2022 06-30-2022 10-Q
8 05-12-2022 03-31-2022 10-Q
9 03-29-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-10-2021 06-30-2021 10-Q
12 05-11-2021 03-31-2021 10-Q
13 03-23-2021 12-31-2020 10-K
14 11-12-2020 09-30-2020 10-Q
15 08-07-2020 06-30-2020 10-Q
16 05-14-2020 03-31-2020 10-Q
17 03-26-2020 12-31-2019 10-K
18 11-01-2019 09-30-2019 10-Q
19 08-05-2019 06-30-2019 10-Q
20 05-15-2019 03-31-2019 10-Q
21 02-19-2019 12-31-2018 10-K
22 11-14-2018 09-30-2018 10-Q
23 08-03-2018 06-30-2018 10-Q
24 05-11-2018 03-31-2018 10-Q
25 03-13-2018 12-31-2017 10-K
26 11-09-2017 09-30-2017 10-Q
27 08-04-2017 06-30-2017 10-Q
28 05-05-2017 03-31-2017 10-Q
29 03-10-2017 12-31-2016 10-K
30 11-04-2016 09-30-2016 10-Q
31 08-04-2016 06-30-2016 10-Q
32 05-05-2016 03-31-2016 10-Q
33 03-10-2016 12-31-2015 10-K
34 11-12-2015 09-30-2015 10-Q
35 08-14-2015 06-30-2015 10-Q
36 06-10-2015 03-31-2015 10-K
37 02-13-2015 12-31-2014 10-Q
38 11-13-2014 09-30-2014 10-Q
39 08-14-2014 06-30-2014 10-Q
40 06-30-2014 03-31-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 pulmatrix-q4-eps-057-beats-104-estimate-sales-220m-beat-177m-estimate

Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(1.04) by ...

 pulmatrix-stops-pur1900-phase-2b-study-patient-enrollment-and-closing-study-in-agreement-with-partner-cipla-to-preserve-cash-and-facilitate-strategic-alternatives

Cipla to take sole responsibility for development of PUR1900, refocused on markets with greatest unmet need and faster path to ...

 pulmatrix-q3-eps-103-beats-105-estimate-sales-175m-miss-186m-estimate

Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(1.03) per share which beat the analyst consensus estimate of $(1.05) by ...

 stocks-that-hit-52-week-lows-on-wednesday

  On Wednesday, 311 stocks hit new 52-week lows.

 stocks-that-hit-52-week-lows-on-tuesday

  On Tuesday, 386 stocks made new 52-week lows.

 pulmatrix-announces-fda-acceptance-of-ind-application-for-pur3100-to-treat-acute-migraine

Pulmatrix received a study may proceed letter for a Phase 2 Study to Evaluate PUR3100, an orally inhaled dry powder formulation...

 stocks-that-hit-52-week-lows-on-friday

  Friday's session saw 225 companies set new 52-week lows.

 stocks-that-hit-52-week-lows-on-wednesday

  On Wednesday, 59 companies achieved new lows for the year.

 stocks-that-hit-52-week-lows-on-tuesday

  On Tuesday, 99 stocks hit new 52-week lows.

 pulmatrix-announces-publication-on-physiologically-based-pharmacokinetic-modelling-of-potential-drug-drug-interactions-with-pur1900-orally-inhaled-itraconazole

Results demonstrate a low likelihood of clinically meaningful drug-drug interactions when PUR1900 is administered with medicati...

 hc-wainwright--co-reiterates-buy-on-pulmatrix-maintains-10-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates Pulmatrix (NASDAQ:PULM) with a Buy and maintains $10 price target.

 pulmatrix-q2-eps-104-up-from-136-yoy-sales-184m-up-from-133m-yoy

Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(1.04) per share. This is a 23.53 percent increase over losses of $(1.36)...

 pulmatrix-announces-submission-of-ind-application-to-fda-to-initiate-a-phase-2-trial-of-investigational-drug-pur3100-to-treat-acute-migraine

Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a clinical-stage biopharmaceutical company develo...

 stocks-that-hit-52-week-lows-on-monday

  On Monday, 120 stocks hit new 52-week lows.

 hc-wainwright--co-reiterates-buy-on-pulmatrix-maintains-10-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates Pulmatrix (NASDAQ:PULM) with a Buy and maintains $10 price target.

 pulmatrix-q1-eps-122-up-from-151-yoy-sales-150m-up-from-116m-yoy

Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(1.22) per share. This is a 19.21 percent increase over losses of $(1.51)...

 stocks-that-hit-52-week-lows-on-thursday

  On Thursday, 185 companies achieved new lows for the year.

 pulmatrix-announces-year-end-and-q4-financial-2022-results-and-provides-corporate-update-356m-in-cash-and-cash-equivalents-at-the-end-of-2022-providing-cash-runway-into-q2-2024

PUR1900 Phase 2b study dosed first patients in Q1 2023 PUR3100 Phase 1 study achieves positive topline results as announced in...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION